Literature DB >> 7493145

The effect of intrathecal bupivacaine with combined fentanyl in cesarean section.

C C Chu1, S S Shu, S M Lin, N W Chu, Y K Leu, S K Tsai, T Y Lee.   

Abstract

BACKGROUND: The use of neuraxial opioids has gained popularity over the last few years; they may augment the analgesia produced by the local anesthetic through direct binding with the specific spinal receptors. Morphine, a lipophobic opioid, may not be optimal as an intrathecal drug for intraoperative analgesia because of its slow onset. The lipophilic opioid, fentanyl for instance, if administered intrathecally, its onset is fast and many of its merits by virtue of its lipophilic property may be seen intraoperatively.
METHODS: Seventy five healthy pregnant women who sustained cesarean section under spinal anesthesia were assessed in a randomized fashion. The spinal anesthetic used was 0.5% hyperbaric bupivacaine. Patients were divided into 5 groups, 15 in each group. Fentanyl 0 (Group I), 7.5 (Group II), 10 (Group III), 12.5 (Group IV) and 15 (Group V) micrograms was respectively added to normal saline to make a total volume of 0.3 ml, which was then added to bupivacaine and administered to patients in a randomized fashion. The effect of analgesia, vital signs and side effects were observed every 5 min during operation and every 30 min after operation.
RESULTS: It was disclosed that all patients in group V and IV had excellent analgesia intraoperatively, while only 33.3% patients in the control group had an analgesia which was qualified as excellent. Complete analgesia (time from injection to first report of pain) also lasted longer in group IV (201.3 +/- 16.4 min, mean +/- SEM) and group V (210.3 +/- 18.6 min) compared with group I (118.9 +/- 10.4 min). The duration of effective analgesia (time from injection to first parental opioid) was increased with the dose of intrathecal fentanyl above 12.5 micrograms (293 +/- 22.4 min). Both complete analgesia and effective analgesia were not significantly different between group IV and group V. Pruritus was the most common side effect. The incidence of shivering decreased significantly in group IV & V as compared with control group.
CONCLUSIONS: The combination of bupivacaine with a dose of fentanyl as low as 7.5 micrograms did not produce actual clinical effects. As the dose of fentanyl was increased to 12.5 micrograms or 15 micrograms the quality of surgical analgesia was better and the postoperative analgesia lasted longer. It seemed that the clinical effect might reach its ceiling at the dose of 12.5 micrograms. Pruritus was the most common side effect, but it was mild.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493145

Source DB:  PubMed          Journal:  Acta Anaesthesiol Sin        ISSN: 0254-1319


  12 in total

1.  The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery.

Authors:  Kevin C Greer; Abdullah S Terkawi; Siny Tsang; Priyanka Singla; Marcel E Durieux; Mohamed Tiouririne
Journal:  Reg Anesth Pain Med       Date:  2017 Sep/Oct       Impact factor: 6.288

2.  A randomized comparison of different doses of intrathecal levobupivacaine combined with fentanyl for elective cesarean section: prospective, double-blinded study.

Authors:  Ilkben Gunusen; Semra Karaman; Asuman Sargin; Vicdan Firat
Journal:  J Anesth       Date:  2011-02-05       Impact factor: 2.078

3.  Comparison of fentanyl and sufentanil added to 0.5% hyperbaric bupivacaine for spinal anesthesia in patients undergoing cesarean section.

Authors:  Jung Hyang Lee; Kum Hee Chung; Jong Yun Lee; Duk Hee Chun; Hyeon Jeong Yang; Tong Kyun Ko; Wan Seop Yun
Journal:  Korean J Anesthesiol       Date:  2011-02-25

4.  Effects of Fentanyl and Morphine on Shivering During Spinal Anesthesia in Patients Undergoing Endovenous Ablation of Varicose Veins.

Authors:  Didem Onk; Tülin Akarsu Ayazoğlu; Ufuk Kuyrukluyıldız; Mehmet Aksüt; Zehra Bedir; İlke Küpeli; Oruç Alper Onk; Ayşin Alagöl
Journal:  Med Sci Monit       Date:  2016-02-12

5.  Perioperative analgesia after intrathecal fentanyl and morphine or morphine alone for cesarean section: A randomized controlled study.

Authors:  Wojciech Weigl; Andrzej Bieryło; Monika Wielgus; Świetlana Krzemień-Wiczyńska; Marcin Kołacz; Michał J Dąbrowski
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 6.  Effects of intrathecal opioids on cesarean section: a systematic review and Bayesian network meta-analysis of randomized controlled trials.

Authors:  Hiroyuki Seki; Toshiya Shiga; Takahiro Mihara; Hiroshi Hoshijima; Yuki Hosokawa; Shunsuke Hyuga; Tomoe Fujita; Kyotaro Koshika; Reina Okada; Hitomi Kurose; Satoshi Ideno; Takashi Ouchi
Journal:  J Anesth       Date:  2021-08-02       Impact factor: 2.078

7.  Intrathecal fentanyl for prevention of shivering in spinal anesthesia in cesarean section.

Authors:  Ali Sadegh; Nasrin Faridi Tazeh-Kand; Bita Eslami
Journal:  Med J Islam Repub Iran       Date:  2012-05

8.  Analgesic efficacy of intrathecal fentanyl during the period of highest analgesic demand after cesarean section: A randomized controlled study.

Authors:  Wojciech Weigl; Andrzej Bierylo; Monika Wielgus; Swietlana Krzemień-Wiczyńska; Iwona Szymusik; Marcin Kolacz; Michal J Dabrowski
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Effect of intrathecal lipophilic opioids on the incidence of shivering in women undergoing cesarean delivery after spinal anesthesia: a systematic review and bayesian network meta- analysis of randomized controlled trials.

Authors:  Yamini Subramani; Mahesh Nagappa; Kamal Kumar; Lee-Anne Fochesato; Moaz Bin Yunus Chohan; Yun Fei Zhu; Kevin Armstrong; Sudha Indu Singh
Journal:  BMC Anesthesiol       Date:  2020-08-26       Impact factor: 2.217

10.  Postoperative Analgesia with Intrathecal Nalbuphine versus Intrathecal Fentanyl in Cesarean Section: A Double-Blind Randomized Comparative Study.

Authors:  Tripat Kaur Bindra; Parmod Kumar; Garima Jindal
Journal:  Anesth Essays Res       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.